Structure Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Structure Therapeutics Inc in the second quarter 2026?
Structure Therapeutics Inc recorded a cumulative net loss of $-215 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -16.89%.

Within the Major Pharmaceutical Preparations industry 88 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1740 to 2777.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	75.42 %	75.48 %	75.34 %	-14.14 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-215	-170	-141	-211	-179
Return On Equity (TTM)	-16.89 %	-15.12 %	-14.55 %	-26.08 %	-21.31 %
GPCR's Total Ranking	# 2777	# 1740	# 1698	# 2617	#
Equity (TTM) in Millions	1,354	1,447	1,516	770	772
Seq. Equity Change	-6.41 %	-4.57 %	96.93 %	-0.27 %	-6.37 %
Seq. Net Income Change	-	-	-	-	-

Back to GPCR Management Effectiveness >> GPCR's 5 Years Annual ROE >> Compare GPCR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 89
Sector	# 265
Overall	# 2777

Return On Equity Statistics
High	Average	Low
-14.55 %	-20.5 %	-32.69 %
(Dec 31 2025)		(Dec 31 2023)

News about Structure Therapeutics Inc Return on Equity ROE

Advancements in Obesity Management Phase 2b ACCESS Study for GSBR-1290 Demonstrates Promising Potential

The rising prevalence of obesity has necessitated the development of effective pharmacological interventions. Structure Therapeutics oral small molecule GLP-1 receptor agonist, GSBR-1290, is currently under investigation in the Phase 2b ACCESS clinical study aimed at evaluating its efficacy and safety over a 36-week period. Preliminary results from earlier Phase 2a studies have highlighted GSBR-1290’s potential as a well-tolerated therapy with minimal adverse events. This article discusses the latest updates from the ACCESS study, emphasizing the clinical implications for obesity treatment. Obesity is a multifactorial disease posing significant health risks, including cardiovascular disease, diabetes, and various other comorbidities. Despite the availability of lifestyle interventions, the need for pharmacotherapy remains critical. GLP-1 receptor agonists have emerged as a promising class of drugs for managing obesity. Structure Therapeutics GSBR-1290, an oral small molecule GLP-1 receptor agonist, represents a novel approach, aiming to improve patient adherence and outcomes.

Structure Therapeutics Unveils Ambitious Public Offering Plans, Aiming to Revolutionize Biopharmaceutical Industry

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
SAN FRANCISCO, June 03, 2024 - Structure Therapeutics Inc. (NASDAQ: GPCR), a leading biopharmaceutical company specializing in the development of innovative oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has made an exciting announcement. The company recently filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed underwritten public offering.
The offering will consist of 8,000,000 American depositary shares (ADSs), with each ADS representing three ordinary shares. Structure Therapeutics also plans to offer pre-funded warrants to certain investors in lieu of ADSs. These warrants will allow investors to purchase ordinary shares represented by ADSs in the underwritten public offering. The price of each pre-funded warrant will be set at the price per ADS at which the ADSs are being sold to the public, minus $0.0001, which will be the per share exercise price of each warrant.

GPCR Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023
Total Equity in Millions	1,516	865	453	0	0
Y / Y Equity Change	75.34 %	90.93 %	-	-	-
Net Income in Millions	-141	-123	-90	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-9.31 %	-14.17 %	-19.79 %	-	-

Back to GPCR Management Effectiveness >> GPCR's 5 Years Annual ROE >> Compare GPCR ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GPCR's' Return on Equity at Yahoo Finance
GPCR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GPCR's Competitors
Subscribers only: Roe for Structure Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for GPCR's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-08T01:17:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.